Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

• Published in: Supportive care in cancer Vol. 24; no. 1; pp. 447 - 455
• Main Authors: Stopeck, Alison T., Fizazi, Karim, Body, Jean-Jacques, Brown, Janet E., Carducci, Michael, Diel, Ingo, Fujiwara, Yasuhiro, Martín, Miguel, Paterson, Alexander, Tonkin, Katia, Shore, Neal, Sieber, Paul, Kueppers, Frank, Karsh, Lawrence, Yardley, Denise, Wang, Huei, Maniar, Tapan, Arellano, Jorge, Braun, Ada
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2016; Springer; Springer Nature B.V
• Subjects: Administration, Cutaneous; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - adverse effects; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Breast cancer; Breast Neoplasms; Cancer metastasis; Cancer research; Cancer therapies; Care and treatment; Clinical trials; Denosumab - administration & dosage; Denosumab - adverse effects; Diphosphonates - administration & dosage; Diphosphonates - adverse effects; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Infusions, Intravenous; Long-Term Care; Male; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Nursing; Nursing Research; Oncology; Original; Original Article; Pain Medicine; Prostate cancer; Prostatic Neoplasms; Rehabilitation Medicine; Safety and security measures; Treatment Outcome; Zoledronic Acid; Zoledronic acid; Breast cancer; Denosumab; Prostate cancer; Osteonecrosis of the jaw; Bone metastases

Purpose Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied. Here, we describe safety results of extended denosumab therapy in patients with bone metastases from the open-label extension phase of two ph...